Protagenic Therapeutics Files Definitive Proxy Statement
Ticker: PTIXW · Form: DEF 14A · Filed: Mar 10, 2025 · CIK: 1022899
| Field | Detail |
|---|---|
| Company | Protagenic Therapeutics, Inc.\New (PTIXW) |
| Form Type | DEF 14A |
| Filed Date | Mar 10, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, shareholder-meeting
TL;DR
Protagenic Proxy Statement is IN: Shareholders vote on directors & company matters.
AI Summary
Protagenic Therapeutics, Inc. filed its definitive proxy statement on March 10, 2025, for its annual meeting. The filing outlines the company's governance, executive compensation, and proposals to be voted on by shareholders. Key details regarding director nominations and other corporate matters are included.
Why It Matters
This filing provides shareholders with crucial information to make informed voting decisions on company leadership and strategic direction.
Risk Assessment
Risk Level: low — This is a routine proxy filing and does not contain new material financial or operational information.
Key Numbers
- 20250310 — Filing Date (The definitive proxy statement was filed on this date.)
- 20250307 — Period of Report (The reporting period for the proxy statement.)
Key Players & Entities
- Protagenic Therapeutics, Inc. (company) — Registrant
- 149 FIFTH AVENUE, SUITE 500, NEW YORK, NY 10010 (address) — Business and Mail Address
- Atrinsic, Inc. (company) — Former Company Name
- NEW MOTION, INC. (company) — Former Company Name
- MPLC, Inc. (company) — Former Company Name
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or definitive proxy statement, is used by companies to solicit proxies from shareholders for an upcoming meeting, providing details on matters to be voted upon, such as director elections and executive compensation.
Who is the registrant for this filing?
The registrant for this filing is Protagenic Therapeutics, Inc.
When was this definitive proxy statement filed?
This definitive proxy statement was filed on March 10, 2025.
What is the company's primary business address?
The company's business address is 149 FIFTH AVENUE, SUITE 500, NEW YORK, NY 10010.
Has Protagenic Therapeutics, Inc. operated under other names previously?
Yes, Protagenic Therapeutics, Inc. has operated under the former names Atrinsic, Inc., NEW MOTION, INC., and MPLC, Inc.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on March 10, 2025 regarding Protagenic Therapeutics, Inc.\new (PTIXW).